CinCor is a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases. Baxdrostat is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. Baxdrostat has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure.

OUR PATH

We are evaluating the efficacy and safety profile of baxdrostat as a potential treatment for the broader hypertensive population, including different subpopulations of hypertensive patients who have not achieved blood pressure control despite treatment. We have completed a Phase 2 clinical trial, which we refer to as our BrigHtn trial, of baxdrostat in patients whose blood pressure is not controlled despite treatment with three or more antihypertensive agents, including a diuretic, which is referred to as treatment resistant hypertension, or rHTN. We reported positive topline BrigHtn results in August 2022.  We have an ongoing Phase 2 clinical trial, which we refer to as our HALO trial, in patients with whose blood pressure is not controlled despite treatment with one or more antihypertensive agent, which is referred to as uncontrolled hypertension, or uHTN.  An open-label extension clinical trial for patients previously enrolled in our HALO trial has been initiated to evaluate the long-term safety and effectiveness of baxdrostat, which we refer to as our OLE trial.

In addition to hypertension, we are developing baxdrostat for the treatment of primary aldosteronism, or PA, and we are exploring its utility in ameliorating complications of chronic kidney disease, or CKD. In 2021, we initiated a Phase 2 clinical trial of baxdrostat in patients with PA, which we refer to as our spark-PA trial. In 2022, we initiated a Phase 2 clinical trial in patients with CKD who have uncontrolled blood pressure, which is referred to as our figHtn-CKD trial.